Inventiva S.A.
NASDAQ:IVA · NASDAQ Global Market
+$0.02 today
Vol 3.55M · Avg 0.45M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:IVA · Revenue to Net Income
Key Ratios
Analysis
$13.7M of revenue converted into -$537.0M of net income for the selected period. Gross margin is -952.9% and net margin is -155629.2%, showing how much revenue survives after costs and taxes. EPS is $-5.44, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.5M -51.3% | $9.2M -47.4% | $17.5M +43.5% | $12.2M +190.4% | $4.2M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.8M -28.0% | $3.9M +16974.4% | -$23.0K -102.3% | $995.0K -2.2% | $1.0M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $1.5M -83.6% | $9.2M -47.4% | $17.5M +2.6% | $17.1M +306.7% | $4.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 33.7% -66.3pp | 100.0% -0.1pp | 100.1% -39.9pp | 140.1% +40.1pp | 100.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $83.6M -8.0% | $90.9M -17.4% | $110.0M +81.9% | $60.5M +24.8% | $48.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $53.9M +215.2% | $17.1M +9.6% | $15.6M +0.7% | $15.5M +34.5% | $11.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $137.4M +28.7% | $106.8M -11.2% | $120.2M +62.0% | $74.2M +31.7% | $56.3M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $2.8M -46.2% | $5.2M +100.0% | $2.6M +198.7% | $870.0K +1.4% | $858.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$128.2M +23.0% | -$166.5M -63.2% | -$102.0M -81.3% | -$56.3M -6.7% | -$52.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -2858.6% -1048.1pp | -1810.4% -1226.6pp | -583.9% -121.7pp | -462.2% +795.9pp | -1258.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$130.9M -34.2% | -$97.6M +5.0% | -$102.7M -79.8% | -$57.1M -9.6% | -$52.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -2921.0% -1860.3pp | -1060.6% -473.0pp | -587.7% -118.8pp | -468.9% +773.7pp | -1242.6% | 16.6% | 24.1% | 22.0% |
| Interest Income | $2.8M +147.5% | $1.1M +21.0% | $945.0K +142.3% | $390.0K +584.2% | $57.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $32.3M +165.2% | $12.2M +135.2% | $5.2M +632.4% | $707.0K +412.3% | $138.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$211.4M -144.8% | -$86.3M -1114.4% | -$7.1M -352.5% | $2.8M -0.9% | $2.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$342.3M -86.1% | -$183.9M -67.5% | -$109.8M -102.3% | -$54.3M -10.2% | -$49.3M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -7636.1% -5636.7pp | -1999.4% -1371.0pp | -628.4% -182.6pp | -445.8% +729.0pp | -1174.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $22.0K -93.0% | $313.0K -48.4% | $607.0K +3135.0% | -$20.0K -105.5% | $364.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$340.2M -84.7% | -$184.2M -66.8% | -$110.4M -103.5% | -$54.3M -9.3% | -$49.6M | $4.9B | $4.8B | $4.7B |
| Net Margin | -7587.8% -5585.1pp | -2002.7% -1370.9pp | -631.8% -186.2pp | -445.6% +737.9pp | -1183.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +48.6% | -$4 -45.7% | -$2 -85.5% | -$1 -3.1% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +48.6% | -$4 -45.7% | -$2 -85.5% | -$1 -3.1% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $186.8M +259.4% | $52.0M +14.6% | $45.4M +9.4% | $41.4M +5.8% | $39.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $186.8M +259.4% | $52.0M +14.6% | $45.4M +9.4% | $41.4M +5.8% | $39.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Genfit S.A.
GNFT
$445.68M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$293.87M
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
$280.21M
Cartesian Therapeutics, Inc.
NASDAQ:RNAC
$279.42M
Orchestra BioMed Holdings, Inc.
NASDAQ:OBIO
$235.33M
Eupraxia Pharmaceuticals Inc.
NASDAQ:EPRX
$213.10M
Avalo Therapeutics, Inc.
NASDAQ:AVTX
$170.43M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Invivyd, Inc.
NASDAQ:IVVD
$128.08M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$119.12M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does IVA generate?
Inventiva S.A. (IVA) reported $4.48M of revenue in fiscal 2025.
Is IVA profitable?
Inventiva S.A. (IVA) reported -$340,161,126.00 of net income, with a net margin of -7587.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.